Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $550,438 | $525,946 | $445,824 | $558,316 |
| - Cash | $92,997 | $94,582 | $57,903 | $83,014 |
| + Debt | $34,229 | $35,158 | $36,207 | $32,932 |
| Enterprise Value | $491,670 | $466,522 | $424,128 | $508,234 |
| Revenue | $300,004 | $301,965 | $279,037 | $266,257 |
| % Growth | -0.6% | 8.2% | 4.8% | – |
| Gross Profit | $171,027 | $178,709 | $166,087 | $156,586 |
| % Margin | 57% | 59.2% | 59.5% | 58.8% |
| EBITDA | $59,009 | $50,716 | $12,949 | $52,930 |
| % Margin | 19.7% | 16.8% | 4.6% | 19.9% |
| Net Income | $36,256 | $26,642 | -$14,948 | $27,218 |
| % Margin | 12.1% | 8.8% | -5.4% | 10.2% |
| EPS Diluted | 103.68 | 72.37 | -38.58 | 67.97 |
| % Growth | 43.3% | 287.6% | -156.8% | – |
| Operating Cash Flow | $60,928 | $72,649 | $37,147 | $46,043 |
| Capital Expenditures | -$6,662 | -$10,687 | -$24,588 | -$35,841 |
| Free Cash Flow | $54,266 | $61,962 | $12,559 | $10,202 |